ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.

Giampaolo Bianchini, Luca Gianni, Balázs Győrffy et al.|Journal of Clinical Oncology|2021

Cited by 1